These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16226883)

  • 1. Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin.
    Wang SN; Deng YH; Xu H; Wu HB; Qiu YK; Chen DW
    Eur J Pharm Biopharm; 2006 Jan; 62(1):32-8. PubMed ID: 16226883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.
    Wang S; Xu H; Xu J; Zhang Y; Liu Y; Deng YH; Chen D
    AAPS PharmSciTech; 2010 Jun; 11(2):870-7. PubMed ID: 20490957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The distribution of azidothymidine palmitate galactosylated liposomes in mice].
    Wu HB; Deng YH; Wang SN; Zhou XY; Wang N; Shi L
    Yao Xue Xue Bao; 2007 May; 42(5):538-44. PubMed ID: 17703780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor.
    Sliedregt LA; Rensen PC; Rump ET; van Santbrink PJ; Bijsterbosch MK; Valentijn AR; van der Marel GA; van Boom JH; van Berkel TJ; Biessen EA
    J Med Chem; 1999 Feb; 42(4):609-18. PubMed ID: 10052968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galactosylated liposomes as oligodeoxynucleotides carrier for hepatocyte-selective targeting.
    Yu F; Jiang T; Zhang J; Cheng L; Wang S
    Pharmazie; 2007 Jul; 62(7):528-33. PubMed ID: 17718195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
    J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice].
    Xu XY; Zhou JP; Li L; Zhang Y; Huo MR; Wang X; Lü L
    Yao Xue Xue Bao; 2008 Jul; 43(7):743-8. PubMed ID: 18819480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents.
    Wu J; Liu P; Zhu JL; Maddukuri S; Zern MA
    Hepatology; 1998 Mar; 27(3):772-8. PubMed ID: 9500706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.
    Eliaz RE; Szoka FC
    Cancer Res; 2001 Mar; 61(6):2592-601. PubMed ID: 11289136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposome-based intracellular kinetics of doxorubicin in K562/DOX cells.
    Xu DH; Gao JQ; Liang WQ
    Pharmazie; 2008 Sep; 63(9):646-9. PubMed ID: 18819516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel tetrapeptide, RGDF, mediated tumor specific liposomal doxorubicin (DOX) preparations.
    Du H; Cui C; Wang L; Liu H; Cui G
    Mol Pharm; 2011 Aug; 8(4):1224-32. PubMed ID: 21630705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel local drug delivery system using thermoreversible gel in combination with polymeric microspheres or liposomes.
    Arai T; Benny O; Joki T; Menon LG; Machluf M; Abe T; Carroll RS; Black PM
    Anticancer Res; 2010 Apr; 30(4):1057-64. PubMed ID: 20530409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas.
    Shao K; Hou Q; Duan W; Go ML; Wong KP; Li QT
    J Control Release; 2006 Oct; 115(2):150-7. PubMed ID: 16963144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells.
    Garg M; Madan J; Pandey RS; Sardana S; Katyal A; Chandra R
    Anticancer Drugs; 2012 Sep; 23(8):836-45. PubMed ID: 22407250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier.
    Yuan Y; Wang W; Wang B; Zhu H; Zhang B; Feng M
    J Drug Target; 2013 May; 21(4):367-74. PubMed ID: 23600747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.
    Zhao C; Feng Q; Dou Z; Yuan W; Sui C; Zhang X; Xia G; Sun H; Ma J
    PLoS One; 2013; 8(9):e73860. PubMed ID: 24040096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
    Lopez-Barcons LA; Polo D; Llorens A; Reig F; Fabra A
    Oncol Rep; 2005 Nov; 14(5):1337-43. PubMed ID: 16211306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.